CN112672745A - 叶酸类化合物制剂 - Google Patents

叶酸类化合物制剂 Download PDF

Info

Publication number
CN112672745A
CN112672745A CN201980056865.0A CN201980056865A CN112672745A CN 112672745 A CN112672745 A CN 112672745A CN 201980056865 A CN201980056865 A CN 201980056865A CN 112672745 A CN112672745 A CN 112672745A
Authority
CN
China
Prior art keywords
range
vitamin
formulation
amount
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980056865.0A
Other languages
English (en)
Chinese (zh)
Inventor
马丁·乌尔曼
格尔德·威斯勒
约瑟夫·弗拉默尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aprofore Co
Original Assignee
Aprofore Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprofore Co filed Critical Aprofore Co
Publication of CN112672745A publication Critical patent/CN112672745A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980056865.0A 2018-08-29 2019-08-29 叶酸类化合物制剂 Pending CN112672745A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18191572.9A EP3616700A1 (en) 2018-08-29 2018-08-29 Folate preparations for use in the treatment of eye diseases
EP18191572.9 2018-08-29
PCT/EP2019/073118 WO2020043840A1 (en) 2018-08-29 2019-08-29 Folate preparations

Publications (1)

Publication Number Publication Date
CN112672745A true CN112672745A (zh) 2021-04-16

Family

ID=63449300

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056865.0A Pending CN112672745A (zh) 2018-08-29 2019-08-29 叶酸类化合物制剂

Country Status (7)

Country Link
US (1) US12048702B2 (cg-RX-API-DMAC7.html)
EP (2) EP3616700A1 (cg-RX-API-DMAC7.html)
JP (1) JP7649962B2 (cg-RX-API-DMAC7.html)
CN (1) CN112672745A (cg-RX-API-DMAC7.html)
AU (1) AU2019331652B2 (cg-RX-API-DMAC7.html)
CA (1) CA3110285A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020043840A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268167A1 (zh) * 2021-06-24 2022-12-29 连云港金康和信药业有限公司 叶酸类衍生物在制备治疗隐形眼镜不适及干眼症药物的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461826A1 (en) * 2017-09-29 2019-04-03 Aprofol AG Multifunctional folate salts
EP3646873A1 (en) * 2018-10-31 2020-05-06 Aprofol AG Folate salts
EP3875094A1 (en) * 2020-03-02 2021-09-08 Aprofol AG Folate preparations for the treatment of ocular diseases
GB202302379D0 (en) * 2023-02-20 2023-04-05 Upl Mauritius Ltd Agrochemical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087479A1 (en) * 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
US20110319356A1 (en) * 2010-06-25 2011-12-29 Buell Brian W Methods Of Treating Optic Disorders
DE202015105351U1 (de) * 2015-10-09 2016-01-07 Apotheke am Schlossplatz Inh. Mario Ganster e.K. Diätetische Zusammensetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2633868A1 (en) * 2005-12-20 2007-07-05 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
US20080113900A1 (en) 2006-09-22 2008-05-15 Brasch Nicola E Pharmaceutical compositions and therapeutic applications for the use of a synthetic vitamin B12 derivative, glutathionylcobalamin
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
EP2799061A1 (en) * 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087479A1 (en) * 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
US20110319356A1 (en) * 2010-06-25 2011-12-29 Buell Brian W Methods Of Treating Optic Disorders
DE202015105351U1 (de) * 2015-10-09 2016-01-07 Apotheke am Schlossplatz Inh. Mario Ganster e.K. Diätetische Zusammensetzung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRAIG J BROWN: "Preservation of retinal structure and function after cilioretinal artery occlusion: a case report", 《INTERNATIONAL MEDICAL CASE REPORTS JOURNAL》, pages 31 *
FRANCESCO SCAGLIONE等: "Folate, folic acid and 5-methyltetrahydrofolate are not the same thing", 《XENOBIOTICA》, vol. 44, no. 5, XP055639461, DOI: 10.3109/00498254.2013.845705 *
JAE H. KANG等: "A Prospective Study of Folate, Vitamin B6, and Vitamin B12 Intake in Relation to Exfoliation Glaucoma or Suspected Exfoliation Glaucoma", 《JAMA OPHTHALMOLOGY》, vol. 132, no. 5, pages 551 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268167A1 (zh) * 2021-06-24 2022-12-29 连云港金康和信药业有限公司 叶酸类衍生物在制备治疗隐形眼镜不适及干眼症药物的应用

Also Published As

Publication number Publication date
WO2020043840A1 (en) 2020-03-05
JP2021535131A (ja) 2021-12-16
EP3616700A1 (en) 2020-03-04
EP3843744A1 (en) 2021-07-07
JP7649962B2 (ja) 2025-03-24
AU2019331652B2 (en) 2025-01-23
CA3110285A1 (en) 2020-03-05
US12048702B2 (en) 2024-07-30
AU2019331652A1 (en) 2021-03-18
US20210308139A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP7649962B2 (ja) 葉酸塩製剤
US6299896B1 (en) Multi-vitamin and mineral supplement
US6361800B1 (en) Multi-vitamin and mineral supplement
US11478506B2 (en) Dietary supplements
US10265343B2 (en) Kits and methods for nutrition supplementation
Bernstein et al. The emerging roles of the macular pigment carotenoids throughout the lifespan and in prenatal supplementation
US12285423B2 (en) Composition for enhancing mitochondrial function
US20040082536A1 (en) Multi-vitamin and mineral supplement
US11246834B2 (en) Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
JP2021535131A5 (cg-RX-API-DMAC7.html)
JP2008508305A (ja) 栄養補充のための組成物および方法
JP2026076176A (ja) 眼科疾患の治療のための葉酸製剤
AU741525B2 (en) Composition and method for treating macular disorders
EP2393490A1 (en) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
KR100816140B1 (ko) 일차성 두통의 치료에서 비타민 혼합물의 용도
Tornatore Reactions to psychotropic medication
US12383520B2 (en) Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder
WO2005072721A1 (ja) 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物
Dimmel et al. Vitamins, amino acids, and drugs and formulations used in nutrition
JP2025172167A (ja) 睡眠の質の改善剤
Zhang et al. Nonprescribed Systemic Drugs and Therapies
IT202000027897A1 (it) Composizione di combinazione per il trattamento di una disfunzione erettile
Neill Vitamins in Eye-work

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination